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Abstract: In the urinary bladder, the main source of NO seems to be the urothelium and the 
underlying suburothelium. In this study, we aimed to characterize how receptors in the 
human urothelium regulate the production and release of NO. For this, we cultured two 
human urothelial cell lines - the normal immortalized cell line UROtsa and the malignant cell 
line T24. These were treated with an array of agonists and antagonists with affinity for 
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adrenergic, muscarinic and purinergic receptors. The production of NO and expression of 
nitric oxide synthase (NOS) was studied by immunocytochemistry and western blotting. The 
amount of released NO was measured indirectly by detecting nitrite using amperometry and a 
Griess reaction kit. The results showed that NO, endothelial NOS and inducible NOS were 
predominantly produced and expressed in the close vicinity of the nucleus in untreated 
human urothelial cells. Upon treatment with a beta-adrenoceptor agonist, but not any of the 
other agonists or antagonists, the pattern of NO production changed, showing a more even 
production throughout the cytosol. The pattern of expression of endothelial NOS changed in a 
similar way upon dobutamine treatment. The release of nitrite, as a measurement of NO, 
increased following treatment with dobutamine from 0.31±0.029 to 1.97±0.18 nmol and 
0.80±0.12 to 3.27±0.24 nmol in UROtsa and T24, respectively. In conclusion, our results 
show that the expression of NOS and production of NO as well as the release of NO from 
human urothelial cells is regulated by beta-adrenoceptor activation.  
 
As recently reviewed [1], numerous studies have been published which detail the various 
roles of nitric oxide (NO) in the urinary bladder. When comparing data from these studies, 
they appear to be somewhat contradictory, since beneficial effects according to one study can 
be contradicted by data from another. This has led to difficulties when trying to propose 
pharmacological treatments that regulate NO. Despite the dissonance among data in the 
literature, NO has been shown to be involved in several bladder diseases, including bladder 
cancer [2, 3]. NO is also involved in inflammatory diseases in the urinary bladder [4-6], even 
though it is still somewhat unclear whether the increase in NO/NO synthase (NOS) is a 
secondary consequence of inflammation or an integral part of the protective inflammatory 
response [7]. While immunohistochemical staining has revealed the presence of endothelial 
and inducible NOS (eNOS and iNOS) in the sub-urothelium [8], the main source of NO in 
the bladder seems to be the urothelium [9-11]. This is especially evident during certain 
disease states in which the levels of expression of NOS can be altered [8, 12].  
The urothelium consists of 3-5 layers of transitional epithelial cells that line the major parts 
of the renal pelvis, ureters, urinary bladder and urethra. The innermost, apical, surface of the 
urothelium is covered by a thick layer of glycoproteins and basolaterally the suburothelium 
can be found, which harbours nerves, blood vessels, connective tissue and various other 
interstitial cells. Release of NO from the urothelium can be induced by bladder wall 
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distension, changes in pH or composition of urine or by activation of a number of receptors 
present in the urothelium. An array of receptors including muscarinic, adrenergic, purinergic 
and vanilloid receptors are expressed in the urothelium (for full review, see Winder et al., 
2014). Release of urothelial nitric oxide by activation of adrenoceptors has previously been 
demonstrated in rats [14]. The same group later showed that activation of beta-adrenoceptors 
also increased urothelial eNOS in rats [15]. During certain disease states, i.e. cystitis, it has 
been shown that NO can be released upon activation of muscarinic receptors of the M5 
subtype [11]. These receptors are mainly expressed in the urothelium [8], however, it has not 
been entirely proven that the urothelium is the source of NO. Tentatively, the activation of 
urothelial muscarinic M5 receptors could lead to the release of an unidentified substance that 
in turn causes release of NO in the suburothelium.  
Apart from its involvement during cystitis, several studies have shown that NO can regulate 
contraction of the bladder smooth muscle [16], in particular by mediating relaxation of the 
bladder neck [17]. Even though expression of all three subtypes of beta-adrenoceptors have 
been identified in the human bladder, there seems to be a predominant expression of β1- and 
β2-adrenoceptors in the urothelium and, conversely, of β3-adrenoceptors in the detrusor [18]. 
Since activation of β3-adrenoceptors in endothelial cells causes release of NO and subsequent 
vasorelaxation [19], it has been assumed that treatment of overactive bladder (OAB) with a 
β3-adrenoceptor agonist causes relaxation of the detrusor in a similar fashion. However, this 
remains to be proven.  
Since NO has been shown to be involved in the onset and development of several urinary 
tract diseases, pharmacological treatment regulating the levels of NO, especially in the 
urothelium, has been proposed. It is possible that pharmacological treatments affecting the 
lower urinary tract that are already used in clinical practice, i.e. treatment against overactive 
bladder, affect levels of NO. However, until more precise mechanisms of production and 
release of NO have been unraveled, it will not be possible to develop drugs that specifically 
and selectively affect levels of NO in humans without causing significant side effects. Most 
previous studies on NO examine expression and effects of NOS and not NO per se. Further, 
to our knowledge, the release of NO from the human urothelium has not previously been 
quantified. The aim of the current study therefore was to quantitatively and qualitatively 
examine how the production and release of NO in a normal and a malignant human urothelial 
cell line is regulated by activation of autonomic receptors. This was achieved by treating the 
cells with the non-selective muscarinic agonist methacholine, the non-selective muscarinic 
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antagonist atropine, the P2 purinoceptor agonist adenosine 5´-triphosphate (ATP), the P1 
purinoceptor agonist adenosine, the alpha-adrenoceptor agonist phenylephrine, the beta-
adrenoceptor agonist dobutamine, the alpha-adrenoceptor antagonist phentolamine or the 
beta-adrenoceptor antagonists propranolol (β1/2-selective) or L-748,337 (β3-selective) for 
either 24 or 72 hr, in order to study short- and long-term exposure, respectively, and examine 
how the treatments affected production and release of NO.  
 
Methods and materials 
Two human urothelial cell lines, UROtsa and T24, were used in this study. The UROtsa cell 
line is an immortalized cell line derived from the ureter urothelial lining and shares several 
characteristics with cells that are found in the intermediate layers of the normal human 
urothelium [20, 21]. The T24 cell line is a non-tumourigenic transitional carcinoma cell line, 
which is frequently used to study urothelial cancer cell proliferation [22-25]. The UROtsa 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, 
Stockholm, Sweden) and the T24 cells in McCoy’s 5A medium (Sigma-Aldrich) with 10% 
foetal bovine serum and 1% penicillin/streptomycin in a humidified chamber at 37○C in a 
5/95% CO2/O2 atmosphere. Medium was renewed three times weekly, and the cells were 
passaged once a week or when they reached a confluency of 80-90%. Experiments were 
conducted on cells in passage 5-12.  
During splitting, trypsin is stressful for the cells and as a response to this stress they initially 
decrease in size and become rounded. Occasionally, such a stress response was still observed 
in cells 4 hr after a split, but not after 24 or 72 hr. Round cells observed at a later time point 
were instead likely undergoing apoptosis. Careful notice was taken to only include fully 
recovered cells in the evaluation process.  
For visualization of NO-production, cells of both the UROtsa and T24 cell lines were 
trypsinized and cultured in 3 mL of the corresponding cell media in 60 mm non-cytotoxic 
tissue culture dishes (Sarstedt, Newton, USA). Once the cells reached a confluency of 70%, 
they were treated with either phosphate-buffered saline (PBS; serving as control), the beta-
adrenoceptor agonist dobutamine (1*10-4 M; Tocris Bioscience, Bristol, UK), the alpha-
adrenoceptor agonist phenylephrine (5*10-4 M; Sigma-Aldrich), the non-selective muscarinic 
agonist methacholine (1*10-4 M; Sigma-Aldrich), the P2 purinoceptor agonist adenosine 5´-
triphosphate (ATP; 5*10-5 M; Sigma-Aldrich), the P1 purinoceptor agonist adenosine (5*10-5 
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M; Sigma-Aldrich), the non-selective muscarinic antagonist atropine (1*10-4 M; Sigma-
Aldrich), the alpha-adrenoceptor antagonist phentolamine (5*10-5 M; Sigma-Aldrich), the 
β1/2-selective adrenoceptor antagonist propranolol (1*10-5 M; Sigma-Aldrich) or the β3-
selective adrenoceptor antagonist L-748,337 (1*10-5 M; Tocris Bioscience). The chosen drug 
concentrations were based on pilot studies and previous viability data from MTT cell 
proliferation assays [26]. After 24 hr, the cells were treated with 1,2-diaminoanthraquinone 
(DAQ; 1,5 µg/mL) for 30 min. DAQ actively scavenges NO, forming a red fluorophore 
which can be visualized with a rhodamine filter under a fluorescent microscope. During the 
final 20 min. of DAQ staining, for staining of the nucleus, DAPI (Life Technologies, 
Carlsbad, USA; 1 drop/mL of media) was added. Next, the cells were rinsed with pre-heated 
(37○C) PBS and fixed for 15 min. at room temperature with 4% paraformaldehyde (PFA; 
Sigma-Aldrich) in 0.1 M phosphate buffer (500 μL/well) containing Alexa Fluor 488 
phalloidin (Life Technologies), which stains actin filaments allowing for visualization of the 
cytoskeleton. After fixation, the cells were rinsed two times with PBS and were subsequently 
stored in 2 mL PBS until further use.  
For visualization of NOS and receptor protein expression, cells of both the UROtsa and T24 
cell lines were trypsinized and plated in 12-well plates (VWR International, Leuven, 
Belgium) fitted with a cover glass  (15x15 mm; Mänzel, Braunschweig, Germany) at 300,000 
cells/mL in the wells containing cells that were cultured for 24 hr and 100,000 cells/mL in the 
wells containing cells that were cultured for 72 hr. Pilot experiments were conducted in order 
to assure that the amount of plated cells would generate a similar final amount of cells per 
cover glass after 24 and 72 hr, respectively. After a recovery period of 4 hr, the cells were 
treated for 0, 24 or 72 hr with either PBS (serving as control), dobutamine (1*10-4 M) or 
methacholine (1*10-4 M). In the wells containing cells that were treated for 72 hr, the media 
(including drugs) was renewed every 24 hr. After the treatment period, the cells were rinsed 
with preheated PBS and fixed for 15 min. at room temperature with 4% PFA in 0.1 M 
phosphate buffer (500 μL/well). Thereafter, the cover glasses (still placed in the 12-well 
plates) were rinsed for 3 x 10 min. in PBS. This was followed by a 1-hr incubation in 5% 
normal goat or horse serum (Vector Laboratories, Burlington, CA, USA) and 0.25% Triton 
X-100 in PBS (350 µL/well). The cells were subsequently incubated overnight with primary 
antibodies (500 µL/well) against eNOS (1:2000, mouse; AB76198, Abcam, Cambridge, UK), 
iNOS (1:2000, mouse; AB178945, Abcam), muscarinic M1 (1:2000, goat; AB77098, 
Abcam), muscarinic M2 (1:2000, rat, MAB367, Merck-Millipore, Temecula, CA), 
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muscarinic M3 (1:1000, rabbit, AB9018, Merck-Millipore), muscarinic M4 (1:1000, rabbit, 
AB189432, Abcam), muscarinic M5 (1:2000, mouse, AB167567, Abcam), α1 adrenergic 
(1:2000, rabbit, AB3462, Abcam), β1-adrenergic (1:5000, rabbit, AB3442, Abcam), β2-
adrenergic (1:3000, rabbit, AB61778, Abcam) or β3-adrenergic receptors (1:1000, chicken, 
AB59685, Abcam). On the following day, the cells were rinsed for 3 x 10 min. in PBS and 
further incubated for 2 hr with the appropriate secondary antibody (350 µL/well; goat anti-
rabbit Alexa 488 (A11034) and Alexa 568 (A11036); goat anti-mouse Alexa 488 (A11029) 
and Alexa 568 (A11031); goat anti-rat Alexa 488 (A11006) and Alexa 568 (A11077); goat 
anti-chicken Alexa 488 (A11039); and donkey anti-goat Alexa 568 (A11057); all 1:1000; 
Life Technologies/Thermo Fisher Scientific, Waltham, MA). Finally, the cells were rinsed 
for 3 x 10 min., the cover glasses with the grown cells were carefully removed from each 
well and placed on a non-coated glass slide, then cover-slipped using Prolong Gold antifade 
reagent with DAPI (P36931, Life Technologies/Thermo Fisher Scientific).  
All immunostainings and DAQ stainings were visualized using a Nikon 90i fluorescence 
microscope with appropriate filters for Alexa 488, Alexa 568 and DAPI, fitted with a DS-Fi 
camera and the NIS element imaging Software v.4.40 (Nikon Corporation, Tokyo, Japan). In 
order to compare the staining intensities between the treatment groups, all images were 
captured using the same settings, including exposure time, contrast settings and digital gain. 
NO is formed by conversion of L-arginine by NOS. In a biological environment, NO is 
rapidly converted to nitrite and nitrate [27]. Therefore, a common way to quantitatively 
measure release of NO is by measuring the total amount of nitrite and nitrate. Currently, 
supernatant samples were collected and two different methods to quantitatively measure the 
release of NO from the urothelial cells were utilized. 
Cells of both cell lines were plated in T25 flasks (VWR International) at 100,000 and 
180,000 cells/mL of UROtsa and T24 medium, respectively. After a recovery period of 24 hr, 
a confluency of approximately 90% was obtained. Pilot experiments were conducted in order 
to find the optimal seeding density. At this seeding density, the cells are not fully contact-
inhibited but cannot proliferate to a significant degree, which yields metabolically active cells 
that do not replicate extensively. Subsequently, the cells were treated for 0, 24 or 72 hr with 
either PBS (serving as control), dobutamine (1*10-4 M), methacholine (1*10-4 M), 
propranolol (1*10-7 - 1*10-5 M) or L-748,337 (1*10-7 - 1*10-5 M). Supernatant samples for 
the measurement of nitrite levels were collected at each time point. In the flasks that 
contained cells that were treated for 72 hr, the media (including drugs) was renewed every 24 
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hr. A careful cell count was performed after each treatment in order to ensure that significant 
proliferation or cell death had not occurred. 
The Griess diazotization reaction is a common way to quantitatively determine levels of NO 
by measuring nitrite and nitrate [27]. For this purpose, a Griess reagent kit (Thermo Fisher 
Scientific) was used. Briefly, the kit utilizes a two-step reaction in which first the nitrate 
content of all samples is reduced to nitrite by addition of vanadium-HCl (200 mg vanadium 
in 25 mL 1 M HCl; 130 µL of vanadium-HCl per sample). Then, 20 µL of the Griess reagent, 
which was made by mixing equal volumes of N-(1-naphthyl)ethylenediamine and sulfanilic 
acid, was added to all samples in separate wells of a 96-well microplate. The mixture was 
thereafter incubated for 30 min. at room temperature, letting the components undergo the 
Griess reaction. A spectrophotometric microplate reader (Spectramax 340pc, Molecular 
Devices, Synnavale, CA) was used to measure the absorbance of the nitrite-containing 
samples relative to the reference samples at a wavelength of 548 nm. 
Although sensors exist for the monitoring of NO, these are often utilized directly for real-
time monitoring of production from tissues or cells. In our study, we wanted to gain an 
understanding of how release of NO varied following pharmacological interventions over 
longer time frames (e.g. 24-72 hr), and therefore the net amount of nitrite production provides 
a suitable stable indirect marker of NO production. Composite MWCNT microelectrodes (for 
details, see Fagan-Murphy et al. (2016)) were used for the detection of nitrite. Initially, the 
oxidation peak potential for nitrite was obtained using differential pulse voltammetry. This 
was used to define the voltages utilized for amperometric recordings. For measurements, all 
samples were collected as previously described and amperometric measurements were carried 
out for 30 sec. at 0.8 V and 1.2 V against a Ag|AgCl reference electrode. A stainless-steel rod 
was utilized as the counter electrode. The difference in the current between the two voltages 
was used to determine the amount of nitrite present in the various samples. To convert from 
current values to molar amount, the following conversion formula can be used: amount 
(pmoles) = current value (nA) x 83.717.  
To confirm the immunocytochemical changes regarding NOS expression, UROtsa cells were 
cultured in a T75 flask and treated with dobutamine (1*10-4 M), methacholine (1*10-4 M) or 
PBS for 24 or 72 hr.  The cells were subsequently lysed in phosphate EDTA buffer 
containing 5 µM sodium fluoride, 1.5 mM aprotinin, 0.1 mM leupeptin, 0.2 µM sodium 
vanadate, 0.1 mM pepstatin, 5 mM CHAPS, 4 mM Pefablock SC, 6.4 mM deoxycholic acid 
and 2.5% triton X-100. The lysate was thereafter freeze-thawed for three cycles at -80○C and 
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centrifuged at 10,000 x g for 10 min. The pellet was discarded and the Pierce BCA protein 
assay kit (Thermo Fisher Scientific) was used for protein determination of the supernatant. 
Briefly, the protein assay utilizes the reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium. The formation of Cu1+ can be detected by adding a reagent containing bicinchoninic 
acid, which forms a purple-coloured reaction product. The protein content of each sample 
was quantified by comparison to a standard curve of diluted bovine serum albumin. The 
quantified protein samples were mixed with NuPAGE LDS sample buffer (Thermo Fisher 
Scientific) and heated to 70○C for 10 min. to allow for denaturation of the proteins. After 
dilution with distilled water, 12.5 µg of protein from each sample was loaded onto a 
NuPAGE Novex 4-12% bis-tris gel (Thermo Fisher Scientific). For determination of the 
molecular weights of the proteins, two wells were loaded with MagicMark (5 µL; Thermo 
Fisher Scientific). The PowerPac high-current power supply (Bio-Rad, Hercules, CA) and 
XCell SureLock mini-cell electrophoresis system (Thermo Fisher Scientific) were used for 
the immunoblotting procedure upon which the protein samples were electrophoretically 
separated and subsequently transferred to a PVDF membrane (Thermo Fisher Scientific). 
After the transfer, the membrane was blocked for one hour with TBS-T containing 5% non-
fat milk. Thereafter, the membrane was incubated overnight at 4○C with a polyclonal primary 
antibody against β1-adrenoceptors (1:4000; AB3442; Abcam), β2-adrenoceptors (1:2000; 
AB61778; Abcam), β3-adrenoceptors (1:1000; AB59685; Abcam), eNOS (1:1000; AB76198; 
Abcam), iNOS (1:1000; AB178945; Abcam) or beta-actin (1:2000; Sc-47778; Santa Cruz 
Biotechnology, Dallas, TX, USA). All antibodies were diluted in TBS-T containing 5% non-
fat milk. The following day, the membranes were incubated for one hour at room temperature 
with a HRP-conjugated secondary antibody (1:4000 in TBS-T containing 5% non-fat milk) 
targeted against the species in which the primary antibody was raised (Goat ant-rabbit, 
#656120; Goat anti-mouse, #626520; and Goat anti-chicken, #31401; Thermo Fisher 
Scientific). Finally, the ECL Select western blotting detection reagent (GE Healthcare Life 
Sciences, Marlborough, MA) was used to develop the membrane and the chemiluminescence 
was detected in a Fujifilm LAS-1000 Intelligent Dark Box with Image Reader Pro v2.6 
software (Fujifilm Corporation, Tokyo, Japan). After development, the membrane was 
occasionally stripped of antibody by incubation for 15 min. with Restore Western Blot 
stripping buffer (GE Healthcare Life Sciences). No membrane was stripped more than twice.  
All values are expressed as mean±SEM. Statistical significance was determined by two-way 
analysis of variance (ANOVA) followed by a Tukey correction for multiple comparisons. P-
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 9
values <0.05 were regarded as statistically significant. Statistics and graphs were generated 
and parameters computed using GraphPad Prism 6 (GraphPad Software Inc., San Diego, 
USA) and Abode Illustrator CS6, v. 16.0.0 (Adobe Systems, San Jose, USA). For publication 
purposes, figs. 1 and 2 were digitally enhanced using Photoshop v CS6 (Adobe Systems, San 
Jose, USA). All images were enhanced in an identical way.  
 
Results 
In untreated cells of both the UROtsa and T24 urothelial cell line, DAQ staining showed that 
NO predominantly is produced in the close vicinity of the nucleus, as compared to the rest of 
the cytosol (Fig. 1A, 1G). However, upon treatment with dobutamine, the pattern of 
production of NO was altered in both cell lines. As a result, not considering the intensity of 
the stain but instead the staining pattern, the production of NO seemed to be more evenly 
spread throughout the cytosol (Fig. 1B, 1H). The pattern of production of NO was not 
affected by treatment with methacholine, phenylephrine, ATP, adenosine or any of the 
antagonists. Separate from this, we could also observe small, rounded double-cells with a 
high level of NO production that were identified as dividing cells. 
In accordance with the observations of the DAQ staining, we observed a similar pattern of 
expression of iNOS and eNOS antibody staining in untreated urothelial cells, namely a 
predominant expression in the close vicinity of the nucleus (Fig. 2A, 2C, 2G). Dobutamine 
treatment altered the pattern of expression of eNOS (Fig. 2D, 2H), and possibly also iNOS 
(Fig. 2B, 2H), causing a more even distribution throughout the cytosol. Visually, the data also 
suggest a higher expression of eNOS, and possibly lower expression of iNOS, upon 
dobutamine treatment in UROtsa, but not T24, cells. This was also indicated by western blot, 
which showed that dobutamine treatment (72 hr) of UROtsa cells seems to decrease the level 
of expression of iNOS but increase the level of expression of eNOS (Fig. 3).       
Immunocytochemical studies revealed that both cell lines expressed adrenoceptors and 
muscarinic receptors. In line with previous findings in human urothelial cells [29-31], we 
could observe expression of α1-adrenoceptors, all three subtypes of beta-adrenoceptors (β1-3) 
and all five subtypes of muscarinic receptors (M1-M5) (figures not shown). Visually, the 
level of expression or pattern of expression of the receptors did not seem to be altered by 
treatment with dobutamine or methacholine. Further, western blot experiments did not show 
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any change in the expression of beta-adrenoceptors in either cell line after treatment with 
dobutamine or methacholine (data not shown). 
Measurements with an amperometric selective nitrite sensor showed that treatment with 
dobutamine increased the release of NO from both cell lines; from 3.74±0.35 nA (0.31±0.029 
nmol) to 23.52±2.10 nA (1.97±0.18 nmol) and 9.55±1.42 nA (0.80±0.12 nmol) to 39.01±2.91 
nA (3.27±0.24 nmol) in UROtsa (Fig. 4A) and T24 (Fig. 4B), respectively. In contrast, 
methacholine did not significantly increase the release of NO from either of the cell lines. 
These findings were confirmed by measurements with a Griess reagent assay (Fig. 4C and 
4D). The data from the control (PBS) groups in the sensor experiments show that the 
production of NO is stable over time (0-72 hr) in human urothelial cells in culture. In the 
Griess measurement, one can observe a gradual decrease of the amount of released nitrite 
over time. This decrease is most likely due to a higher proliferation rate during these 
experiments, causing contact inhibition. However, all Griess samples were handled and 
collected in the same manner, providing a viable comparison between the treatment groups. 
Both propranolol (β1/2-selective adrenoceptor antagonist) and L-748,337 (β3-selective 
adrenoceptor
 
antagonist) dose-dependently blocked the dobutamine-induced release of NO 
from UROtsa cells (Fig. 5A). Interestingly, propranolol blocked the dobutamine-induced NO 
release at a lower concentration than L-748,337. Meanwhile, while propranolol dose-
dependently blocked the dobutamine-induced release of NO from T24 cells, L-748,337 could 
lower but not completely block the NO release in the concentrations used (Fig. 5B).    
 
Discussion 
In the current study, we have shown that NO release from human urothelial cells, as well as 
production, is regulated by beta-adrenoceptor stimulation. This is in line with previous 
findings in other species [14, 15]. However, a similar comprehensive examination of 
receptor-induced regulation of nitric oxide has not previously been conducted in human 
urothelial cells. Contrarily, the muscarinic receptor agonist methacholine did not alter the 
release of NO from neither immortalized normal nor malignant human urothelial cells, which 
is in slight contrast with previous findings in rats [10, 32]. However, one must acknowledge 
the possibility that the source of NO in the previous studies could be other than the 
urothelium (i.e. the sub-urothelium). Further, some of the previous observations were made 
only during inflammation and seemed to be dependent on an increased expression of 
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muscarinic M5 receptors [11]. In the current study, no changes in autonomic receptor 
expression could be observed. The differences between the current and previous findings thus 
strengthen the proposed idea that the regulation of NO alters during certain disease states. In 
turn, the current and previous findings indicate that both the sympathetic and parasympathetic 
divisions of the autonomic nervous system play a part in the regulation of NO in the urinary 
bladder in vivo.   
By utilizing DAQ, a NO scavenger, we could show that the pattern of production of NO was 
altered by beta-adrenoceptor activation. A similar change in pattern of production of NO has 
not previously been demonstrated in human urothelial cells. This is likely due to the fact that 
most previous studies have focused on the expression of NO synthase (NOS), and not NO per 
se. It is important to note that we have utilized DAQ staining to conduct a qualitative 
evaluation of the pattern of production of NO and not quantitatively measure the total amount 
of fluorescence. A quantitative measurement could possibly even be misleading since it has 
not been shown that NO can be stored intracellularly. Separate from the changes in NO 
production seen during receptor activation, the increase in fluorescence that is observed in 
dividing and apoptotic cells is likely due to the decreased surface volume of the cells, 
concentrating the amount of fluorescence to a smaller area while not affecting the amount of 
fluorescence per se. However, this question should be addressed in a future study in which a 
quantitative measurement of the amount of NO in healthy, dividing and apoptotic cells is 
conducted.  
The fact that the dobutamine-induced release of NO could be dose-dependently blocked by 
the presence of propranolol or L-748,337 shows that the increased release is beta-
adrenoceptor-specific. Even though an increased proliferation could be part of the cause for 
the increased release, careful cell counts were performed, none of which indicated a 
significant amount of proliferation. While propranolol is considered a β1/2-selective 
antagonist, L-748,337 is mainly β3-selective (Ki values of 4.0, 204 and 390 nM for β3-, β2- 
and β1-adrenoceptors, respectively; [33]). Expression of all three subtypes of beta-
adrenoceptors has previously been shown in the human urothelium [30, 34]. Our data show 
that propranolol is a more potent antagonist of dobutamine-induced release of NO than L-
748,337, especially in the T24 cells (Fig. 5). Considering the selectivity profiles of beta-
adrenoceptor antagonists and the fact that L-748,337 should be less selective at its highest 
concentration, our data might imply that the observed NO release is mainly regulated by 
either β1- or β2-adrenoceptors.          
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One can assume three different possible mechanisms, or any combination of these, regarding 
the long-term increase in NO release upon beta-adrenoceptor activation. The first possible 
mechanism is an increase in the expression of beta-adrenoceptors. However, for this to occur, 
longer stimulation periods are usually required. Nevertheless, we examined this possibility, 
without finding any evidence of an increased receptor expression. The second possibility is 
an up-regulation of the expression of any of the NOS isoforms. Many reports have described 
such a mechanism during inflammatory and malignant disease states [2, 8, 35], and we could 
see an up-regulation of eNOS and possible down-regulation of iNOS in UROtsa cells after 72 
hr of dobutamine treatment. We could not, however, see the same changes in the T24 cells. 
The remaining, third, possible mechanism is an increase in the activity of NOS. Considering 
that NO cannot be stored intracellularly, NOS activity should be reflected by changes in the 
levels of extracellular nitrate. Therefore, the increase we observe in NO release can be 
considered a demonstration of either increased NOS activity per se, an up-regulation of NOS 
expression or a combination of both.  
Apart from the previously described mechanisms, one must consider the presence of a NO 
pool, which would not require any increase in expression or activity of NOS or beta-
adrenoceptors. A few reports have been published which either show or discuss the 
possibility of a NO pool [36]. Even though this tentatively could be part of the explanation 
for the increase in NO release that we observe in our acute (24-hr) experiments, the sustained 
increase over 72 hr indicates that it is unlikely to be the main mechanism in place.  
When studying human bladder contraction, it has been shown that the main functional 
receptors are of the muscarinic M3 and β3-adrenoceptor subtypes, with M3 activation causing 
contraction and β3 activation causing relaxation of the detrusor [37-39]. Over-active bladder 
(OAB) has been treated for decades with antimuscarinic drugs, with limited success. 
Recently, mirabegron, a selective β3-agonist, was approved for the treatment of OAB in 
combination with antimuscarinics [40]. Early on, it was suggested that β3-agonists exert their 
relaxatory effect via release of NO [41]. At this time, it was known that in certain disease 
states, i.e. cystitis, activation of urothelial muscarinic receptors, most likely of the M5
 
subtype, can cause release of NO which has an inhibitory effect on rat detrusor contraction 
[11]. However, despite the known relaxatory effects of beta adrenoceptor-induced release of 
NO in other smooth muscle tissue, i.e. arteries, there has not yet been proven to be a clear 
link between β3-adrenoceptor activation, NO and detrusor relaxation [42]. Further, the 
urothelium seems to exert an inhibitory influence on β3-adrenoceptor-induced detrusor 
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relaxation which is not dependent on release of NO from the urothelium [30, 43]. One 
possible physiological effect of beta-adrenoceptor-induced release of NO from urothelium 
may be as a modulator of afferent signalling [44]. However, when discussing the possible 
physiological importance of beta-adrenoceptor-induced NO release from the urothelium and 
how this might apply to current pharmacological treatments, one must take the selectivity 
differences between mirabegron and dobutamine into consideration. Nevertheless, this 
highlights the importance of future functional experiments outlining the exact role of beta-
adrenoceptor-induced release of NO from the urothelium.    
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Fig 1. Representative immunocytochemical images of nitric oxide production in PBS (control) and 
dobutamine treated UROtsa cells.  
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The production of NO was visualized by staining with DAQ (A, B), the cytoskeleton was visualized by 
staining with phalloidin (C, D) and the nucleus was visualized by DAPI-stain (E, F). The stainings 
show a predominant production of NO in the close vicinity of the nucleus in PBS-treated urothelial 
cells (G; control). The distribution pattern was altered following dobutamine treatment (H), where a 
more widespread production could be observed throughout the cytosol.  Arrows indicate distinctive 
points of observation. Scale bar: 25 µm. 
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Fig 2. Representative immunocytochemical images of nitric oxide synthase expression in PBS 
(control) and dobutamine-treated UROtsa cells.   
The expression of iNOS was visualized in red (A, B), the expression of eNOS was visualized in green 
(C, D) and the nucleus was visualized in blue by DAPI-stain (E, F). The iNOS and eNOS expression, 
similar to NO in the DAQ staining, show a predominant expression in the close vicinity of the nucleus 
in PBS-treated (control) cells (A, C, G). The distribution pattern of eNOS, and possibly also iNOS, 
was altered following dobutamine treatment, showing a more even distribution pattern throughout the 
cytosol (B, D, H.) Arrows indicate distinctive points of observation. Scale bar: 25 µm. 
 
 
Fig 3. Western blot image of nitric oxide synthase (NOS) expression in human urothelial cells.   
iNOS (top left panel) and eNOS (top right panel) expression in UROtsa cells after PBS (control), 
dobutamine or methacholine treatment. Bottom panels show the corresponding beta-actin expression 
in the two blots. The beta-actin blots were run in succession after stripping the membranes of the 
iNOS and eNOS antibodies. 
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Fig 4. Receptor-induced nitric oxide (NO) release from human urothelial cells.   
Measurement of NO release from UROtsa and T24 cells after 0, 24 and 72 hr of treatment with PBS, 
methacholine or dobutamine utilizing amperometric sensors (A and B) and Griess reagent assay (C 
and D). While the methacholine treatment did not affect the NO release, the dobutamine-treated 
UROtsa (A) and T24 (B) cell lines displayed a significantly increased release at 24 hr, which was 
sustained over 72 hr. These changes were also confirmed by the Griess reagent assay in both cell 
lines (UROtsa, C; T24, D). * denotes a significant increase compared to the corresponding 0-hr time-
point. Two-way ANOVAs followed by a Tukey post-hoc test, A: F(2,30)=28.85, n=6, p<0.0001;  B: 
F(2,30)=72.52, n=6, p<0.0001; C: F(2,27)=5.19, n=4, p=0.012; and D: F(2,27)=9.67, n=4, 
p=0.0007. 
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Fig 5. Inhibition of receptor-induced nitric oxide (NO) release from human urothelial cells.  
Utilizing amperometric sensors, the effect of selective beta-adrenoceptor antagonists on dobutamine-
induced NO release was evaluated in both UROtsa (A) and T24 (B). In both UROtsa and T24 cells, 
the data demonstrate concentration-dependent inhibition of NO release in the presence of the β1/2-
selective adrenoceptor antagonist propranolol as well as the β3-selective adrenoceptor antagonist L-
748,337. In UROtsa cells (A), propranolol and L-748,337 completely blocked the dobutamine-
induced NO release at a concentration of 10-6 M and 10-5 M, respectively. Similarly, in T24 (B) 
cells, propranolol completely blocked dobutamine-induced NO release at a concentration of 10-6 M 
(after 24 h) or 10-5 M (after 72 hr). However, L-748,337 only partly blocks the dobutamine-induced 
NO release in T24 cells. * denotes a significant increase compared to the corresponding 0-hr time-
point; & denotes a significant difference from dobutamine treatment at the respective time-points. n = 
6 in all groups. Two-way ANOVAs followed by a Tukey post-hoc test, A: Treatment: F(7,120)=115 
and Time: F(2,120)=182, both p<0.0001);  B: Treatment: F(7,120)=204 and Time: F(2,120)=667, 
both p<0.0001).  
 
